Cardamonin attenuates chronic inflammation and tumorigenesis in colon

References

• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol. 2011;11:9–20.
   PubMed Web of Science ®Google Scholar
• Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345:235–241.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409–418.
   PubMed Web of Science ®Google Scholar
• Yadav VR, Prasad S, Sung B, et al. The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol. 2011;11:295–309.
   PubMed Web of Science ®Google Scholar
• De Spirt S, Eckers A, Wehrend C, et al. Interplay between the chalcone cardamonin and selenium in the biosynthesis of Nrf2-regulated antioxidant enzymes in intestinal Caco-2 cells. Free Radic Biol Med. 2016;91:164–171.
   PubMed Web of Science ®Google Scholar
• Hatziieremia S, Gray AI, Ferro VA, et al. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages. Br J Pharmacol. 2006;149:188–198.
   PubMed Web of Science ®Google Scholar
• Zhang T, Yamamoto N, Yamashita Y, et al. The chalcones cardamonin and flavokawain B inhibit the differentiation of preadipocytes to adipocytes by activating ERK. Arch Biochem Biophys. 2014;554:44–54.
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Jeengar MK, Thummuri D, et al. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/beta-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Biofactors. 2016;43(2):152–169.
   PubMed Web of Science ®Google Scholar
• Liao Q, Shi DH, Zheng W, et al. Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats. Eur J Pharmacol. 2010;641:179–186.
   PubMed Web of Science ®Google Scholar
• Jiang FS, Tian SS, Lu JJ, et al. Cardamonin regulates miR-21 expression and suppresses angiogenesis induced by vascular endothelial growth factor. Biomed Res Int. 2015;2015:501581.
   PubMed Web of Science ®Google Scholar
• Ohtsuki T, Kikuchi H, Koyano T, et al. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. Bioorg Med Chem. 2009;17:6748–6754.
   PubMed Web of Science ®Google Scholar
• Yadav VR, Prasad S, Aggarwal BB. Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol. 2012;165:741–753.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sikka S, Siveen KS, et al. Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer. Apoptosis. 2016;22:158–168.
   Web of Science ®Google Scholar
• Jia D, Tan Y, Liu H, et al. Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. Oncotarget. 2016;7:771–785.
   PubMed Web of Science ®Google Scholar
• Qin Y, Sun CY, Lu FR, et al. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-kappaB pathway in vitro. Leuk Res. 2012;36:514–520.
   PubMed Web of Science ®Google Scholar
• Lee MY, Seo CS, Lee JA, et al. Alpinia katsumadai H(AYATA) seed extract inhibit LPS-induced inflammation by induction of heme oxygenase-1 in RAW264.7 cells. Inflammation. 2012;35:746–757.
   PubMed Web of Science ®Google Scholar
• Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2:1998–2004.
   PubMed Web of Science ®Google Scholar
• Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A. 2001;98:13249–13254.
   PubMed Web of Science ®Google Scholar
• Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity. 2012;36:742–754.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Yamamoto N, Murakami A. Cardamonin suppresses nitric oxide production via blocking the IFN-gamma/STAT pathway in endotoxin-challenged peritoneal macrophages of ICR mice. Life Sci. 2011;89:337–342.
   PubMed Web of Science ®Google Scholar
• Ren G, Sun A, Deng C, et al. The anti-inflammatory effect and potential mechanism of cardamonin in DSS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309:G517–27.
   PubMed Web of Science ®Google Scholar
• Nasef NA, Mehta S, Ferguson LR. Susceptibility to chronic inflammation: an update. Arch Toxicol. 2017;91:1131–1141.
   PubMed Web of Science ®Google Scholar
• Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016;15:551–567.
   PubMed Web of Science ®Google Scholar
• Raposo TP, Beirao BC, Pang LY, et al. Inflammation and cancer: till death tears them apart. Vet J. 2015;205:161–174.
   PubMed Web of Science ®Google Scholar
• Lopez SN, Castelli MV, Zacchino SA, et al. In vitro antifungal evaluation and structure-activity relationships of a new series of chalcone derivatives and synthetic analogues, with inhibitory properties against polymers of the fungal cell wall. Bioorg Med Chem. 2001;9:1999–2013.
   PubMed Web of Science ®Google Scholar
• Vogel S, Barbic M, Jurgenliemk G, et al. Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect. Eur J Med Chem. 2010;45:2206–2213.
   PubMed Web of Science ®Google Scholar
• Makita H, Tanaka T, Fujitsuka H, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res. 1996;56:4904–4909.
   PubMed Web of Science ®Google Scholar
• Herencia F, Ferrandiz ML, Ubeda A, et al. Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages. FEBS Lett. 1999;453:129–134.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Ko H, Park JS, et al. Dimethyl cardamonin inhibits lipopolysaccharide-induced inflammatory factors through blocking NF-kappaB p65 activation. Int Immunopharmacol. 2010;10:1127–1134.
   PubMed Web of Science ®Google Scholar
• Han J, Theiss AL. Stat3: friend or foe in colitis and colitis-associated cancer? Inflamm Bowel Dis. 2014;20:2405–2411.
   PubMed Web of Science ®Google Scholar
• Wake MS, Watson CJ. STAT3 the oncogene - still eluding therapy? Febs J. 2015;282:2600–2611.
   PubMed Web of Science ®Google Scholar
• Furtek SL, Backos DS, Matheson CJ, et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol. 2016;11:308–318.
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–746.
   PubMed Web of Science ®Google Scholar
• Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011;471:523–526.
   PubMed Web of Science ®Google Scholar
• Zhang X, Blaskovich MA, Forinash KD, et al. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer. 2014;111:894–902.
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Litvinov IV, Moreau L, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13:3331–3335.
   PubMed Web of Science ®Google Scholar
• Frank DA. StAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003;115:267–291.
   PubMedGoogle Scholar
• Jin BR, Chung KS, Cheon SY, et al. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-kappaB and STAT3 activation. Sci Rep. 2017;7:46252.
   PubMed Web of Science ®Google Scholar
• De Simone V, Franze E, Ronchetti G, et al. Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34:3493–3503.
   PubMed Web of Science ®Google Scholar
• Lin C, Wang L, Wang H, et al. Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways. J Cell Biochem. 2013;114:2061–2070.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shao L, Creighton CJ, et al. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015;6:6281–6294.
   PubMedGoogle Scholar
• Xu ZS, Zhang HX, Li WW, et al. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proc Natl Acad Sci U S A. 2019;116:10447–10452.
   PubMed Web of Science ®Google Scholar
• Wu N, Liu J, Zhao X, et al. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells. Tumour Biol. 2015;36:9667–9676.
   PubMedGoogle Scholar
• Zhang J, Sikka S, Siveen KS, et al. Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer. Apoptosis. 2017;22:158–168.
   PubMed Web of Science ®Google Scholar